India Glycols Limited (INDIAGLYCO)
🎯 Key Takeaways
- India Glycols Limited is navigating a strategic pivot toward high-margin specialty chemicals and biofuels, with ethanol emerging as a key growth driver amid favorable policy tailwinds and global energy shifts. The company is transitioning from a traditional beverages-centric model to a more diversified, value-added portfolio, supported by strong segmental performance in biofuels and chemicals.
- Revenue grew 13.1% QoQ to ₹2,424 in Q3FY25.
- ⚠️ 1) Over-reliance on ethanol and biofuels growth, which is sensitive to crude oil prices, government blending policies, and global geopolitical develop
📖 The Story
India Glycols Limited is navigating a strategic pivot toward high-margin specialty chemicals and biofuels, with ethanol emerging as a key growth driver amid favorable policy tailwinds and global energy shifts. The company is transitioning from a traditional beverages-centric model to a more diversified, value-added portfolio, supported by strong segmental performance in biofuels and chemicals. Despite flat beverage growth, profitability is improving through margin expansion in non-core segments and operational efficiency, signaling a deliberate turnaround rather than organic beverage growth.
📰 What's Happening
In Q3FY26, India Glycols reported revenue of INR9,827 crores (up 8.7% YoY) and PAT of INR293 crores (up 26.8%), driven by robust performance in Bio-Fuels (up 40.9%, EBIT up 103.3%) and Chemicals (EBIT margin improved to 11.7%). Management highlighted progress on its 3x3 ethanol sourcing strategy and favorable ethanol competitiveness due to Ukraine war impacts and stable domestic prices. The company also executed a leadership transition at its subsidiary Ennature Bio Pharma, appointing Akshay Bansal as Additional Director and KMP with a five-year term until 2031, enhancing governance continuity. These moves reflect a focused capital allocation toward high-growth verticals and operational restructuring.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,616 | 1,894 | 1,870 | 2,119 | 2,039 | 2,283 | 2,144 | 2,424 |
| Operating Profit | 100 | 106 | 106 | 107 | 109 | 128 | 120 | 129 |
| OPM % | 5.9% | 5.3% | 5.1% | 4.8% | 5.1% | 5.5% | 5.4% | 5.1% |
| Net Profit | 40 | 51 | 38 | 42 | 42 | 60 | 50 | 57 |
| EPS | ₹12.87 | ₹16.52 | ₹12.27 | ₹13.45 | ₹13.63 | ₹19.50 | ₹16.06 | ₹18.35 |
The company has demonstrated consistent top-line growth over the past four quarters, with revenue expanding from INR1,616 crores in Q4FY23 to INR2,424 crores in Q3FY25, reflecting successful diversification beyond beverages. Profitability trends show OPM stabilizing around 5.1–5.5% and EBITDA margin improving to 15.5% in FY26, supported by margin gains in Chemicals and scale benefits in Bio-Fuels. Despite a 10.4% revenue decline in the Chemicals segment during Q4FY26, EBIT margin expansion indicates cost discipline and product mix improvement. Net profit and EPS trends reflect this structural shift, with PAT growth outpacing revenue growth, suggesting improved operational leverage and margin management.
🔮 Management Outlook & What's Next
Management projects ethanol blending targets of 21–22% and anticipates crude price trends to influence recovery in Ennature Biopharma, indicating sensitivity to global energy markets. The company is actively leveraging policy tailwinds in biofuels and ethanol to drive volume growth, while maintaining focus on margin expansion in Chemicals. The 3x3 ethanol sourcing strategy is positioned as a scalable model to secure feedstock and enhance competitiveness. Management’s commentary underscores a strategic emphasis on capitalizing on global energy transitions, with forward guidance tied to both domestic policy and international crude dynamics shaping business recovery in specialty segments.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Beverages
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Varun Beverages Limited | 1.70 L Cr | 64.7 | — | — | — |
| United Spirits Limited | 96,061 | 66.9 | — | — | — |
| Radico Khaitan Limited | 46,854 | 152.2 | — | — | — |
| United Breweries Limited | 36,165 | 85.1 | — | — | — |
| Allied Blenders and Distillers Limited | 15,534 | 68.7 | 17.2% | 13.7% | 0.69 |
| Tilaknagar Industries Limited | 10,664 | 58.1 | — | — | — |
| India Glycols Limited | 6,832 | 32.7 | — | — | — |
| Piccadily Agro Industries Limited | 5,849 | 42.6 | — | — | — |
| Globus Spirits Limited | 2,626 | 152.3 | — | — | — |
| GM Breweries Limited | 2,023 | 12.9 | — | — | — |
⚠️ Risk Factors
1) Over-reliance on ethanol and biofuels growth, which is sensitive to crude oil prices, government blending policies, and global geopolitical developments such as the Ukraine war. 2) Margin pressure in the Chemicals segment due to volume declines despite EBIT margin improvement, raising concerns about sustainability of profitability gains. 3) Governance and strategic alignment risks at Ennature Bio Pharma following leadership changes, which could impact subsidiary performance and capital allocation efficiency. 4) Commodity price volatility in feedstock and energy inputs could affect cost structures in key segments.
📋 Recent Filings
-
🔴 Corporate Action 31 July 2026India Glycols announced the transfer of Akshay Bansal, Head of Sales & Marketing for Ennature Biopharma, to become an Additional Director and Key Mana...
-
🔴 Corporate Action 31 July 2026India Glycols announced the cessation of Akshay Bansal as a Senior Managerial Personnel effective July 31, 2026, following his transfer to Ennature Bi...
-
🔴 annual report 25 July 2026India Glycols announced that shareholders with unregistered email addresses will receive a web-link to access the FY 2025-26 Annual Report and 42nd AG...
-
🔴 annual report 24 July 2026India Glycols Limited announced its 42nd Annual General Meeting scheduled for 19 August 2026 via video conferencing, with voting instructions, e-votin...
-
🔴 annual report 22 July 2026India Glycols Limited announced its 42nd Annual General Meeting scheduled for 19 August 2026 at 11:00 A.M. IST via video conferencing, with the FY2025...
-
share transfer 3 July 2026India Glycols Limited received a SEBI-mandated certificate from MCS Share Transfer Agent confirming dematerialized securities compliance for the quart...
-
🔴 Corporate Action 3 July 2026India Glycols announced that the National Company Law Tribunal approved its scheme of demerger on July 2, 2026, enabling the separation of Ennature Bi...
-
Announcement 2 July 2026India Glycols Limited announced the appointment of Shri Manoj Kumar Rai as Chief Operating Officer of its wholly owned subsidiary IGL Spirits, effecti...
-
Financial Results 26 June 2026India Glycols Limited announced that its trading window will close on 1 July 2026 and remain closed for 48 hours after the quarterly results declarati...
-
🔴 Financial Results 22 May 2026India Glycols reported FY26 revenue of INR9,827 crores (up 8.7%) and net revenue of INR4,211 crores (up 11.8%), with EBITDA at INR654 crores (up 24.5%...
🧠 Analyst's Read
India Glycols is undergoing a structural transformation with biofuels and Chemicals driving growth, supported by policy tailwinds and margin expansion. The company’s financial trajectory reflects successful diversification, though execution risks remain tied to commodity markets and subsidiary governance. Investors should monitor ethanol blending policy developments, crude price trends, and the operational performance of Ennature Bio Pharma under new leadership as key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-31.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when INDIAGLYCO files new disclosures
Track INDIAGLYCO filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track INDIAGLYCO — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research